Visionary Venture Fund
Visionary is a venture capital firm that invests in the most promising emerging ophthalmology companies in medical devices and pharmaceuticals.
With many breakthrough ophthalmic technologies and platforms on the horizon, Visionary Venture Fund was created to help these companies by contributing clinical expertise, commercialization know-how, and growth capital. We work hand-in-hand with today's most promising ophthalmic technologies to create tomorrow's commercial blockbusters.
We're looking for visionary entrepreneurs, proven teams, and strong IP to create exciting ideas that address large unmet needs in ophthalmology in order to create market-leading businesses. We are a focused venture capital fund from round A to commercialization. Our target investments range from $500K to $5M in financing rounds ranging from $5M to $15MM. We seek to be lead investors and a partner of choice in our deals as we bring a strong KOL doctor partnership to the table.
Visionary’s fund performance net of fees is a 30% IIR, which places it in the top decile of US venture funds.
17 past transactions
Iantech
Series C in 2017
Iantech has developed advanced micro-interventional technology for cataract surgery. After 50 years of conventional phacoemulsification, Iantech introduces a micro-interventional technique designed to deliver energy-free endocapsular lens fragmentation, giving surgeons control, efficiency and new opportunities to improve their surgical technique.
At Iantech, They are working to invent new surgical approaches which can reduce the global footprint of cataract blindness. Using smart, efficient and adaptable micro-interventional technology, Their team is building a new surgical platform to catalyze global outreach efforts as we fight the 25M blindness epidemic in the world
Tarsus Pharmaceuticals
Series B in 2020
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.
Tear Film Innovations Inc.
Series A in 2017
Tear Film Innovations (tearfilm.com) has developed the iLux® Dry Eye Treatment System, a breakthrough medical device for treating evaporative dry eye. Evaporative dry eye is the most prevalent form of dry eye and affects more than 330M people worldwide. The FDA-cleared, handheld iLux device enables an eye care professional to evaluate and treat dry eye patients in less than ten minutes.
Iantech
Series B in 2016
Iantech has developed advanced micro-interventional technology for cataract surgery. After 50 years of conventional phacoemulsification, Iantech introduces a micro-interventional technique designed to deliver energy-free endocapsular lens fragmentation, giving surgeons control, efficiency and new opportunities to improve their surgical technique.
At Iantech, They are working to invent new surgical approaches which can reduce the global footprint of cataract blindness. Using smart, efficient and adaptable micro-interventional technology, Their team is building a new surgical platform to catalyze global outreach efforts as we fight the 25M blindness epidemic in the world
Re-Vana Therapeutics
Seed Round in 2020
Re-Vana Therapeutics Ltd operates as an ocular pharmaceuticals and drug delivery company that focuses on the development and commercialization of biodegradable drug delivery platforms to treat chronic eye diseases such as age-related macular degeneration, diabetic retinopathy, uveitis, and glaucoma. It offers OcuLief, for the treatment of age-related macular degeneration and diabetic retinopathy; and EyeLief, for the treatment of Glaucoma and retina diseases. The company was incorporated in 2016 and is based in Belfast, United Kingdom.
Equinox
Series B in 2018
Equinox is a developer of a medical technology in revolutionizing the treatment of glaucoma and other progressive eye diseases. It uses adjustable, non-surgical, a non-pharmacological system that utilizes the natural laws of physics to balance pressures in and around their eye, enabling doctors to understand glaucoma based on a deep exploration into the physics of the eye pressure.
It was founded in 2014 and is headquartered in Newport Beach, California.
Sydnexis
Series B in 2021
Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia, a major global unmet medical need. Sydnexis manufactures pharmaceutical product for ophthalmic disorder or condition.
Tear Film Innovations Inc.
Series B in 2018
Tear Film Innovations (tearfilm.com) has developed the iLux® Dry Eye Treatment System, a breakthrough medical device for treating evaporative dry eye. Evaporative dry eye is the most prevalent form of dry eye and affects more than 330M people worldwide. The FDA-cleared, handheld iLux device enables an eye care professional to evaluate and treat dry eye patients in less than ten minutes.
Surface Pharmaceuticals
Series A in 2018
Surface Pharmaceuticals is a owner and operator of a pharmaceutical company intended to provide ophthalmology products. The company's medicines uses topical formulations with the patented Klarity delivery vehicle, designed to protect and rehabilitate the ocular surface, enabling patients with dry eye disease to recover on time and properly.
Orasis Pharmaceuticals Ltd
Series C in 2020
Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, and easy-to-use.
Orasis Pharmaceuticals Ltd
Series B in 2018
Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, and easy-to-use.
RxSight, Inc.
Series H in 2017
RxSight, Inc. develops light adjustable lens that enables doctors and patients to predictably optimize vision after cataract surgery through an office based intraocular lens enhancement. It offers RxLAL that enables surgeons to precisely reshape the lens based on the exact amount of visual correction and optimization needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was founded in 1997 and is based in Aliso Viejo, California.
TearClear
Series A in 2017
TearClear is a pharmaceutical company that specializes in providing a class platform of drugs enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface.
The company was founded in 2015 and headquartered in California, United States.
TearClear
Series B in 2020
TearClear is a pharmaceutical company that specializes in providing a class platform of drugs enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface.
The company was founded in 2015 and headquartered in California, United States.
CorneaGen
Series A in 2016
CorneaGen innovates cornea care, from new medical devices and biologics to therapeutics and interventions.
CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea. CorneaGen supports corneal surgeons and their patients with a spectrum of services, including the latest in innovative products, delivery of the highest quality tissue, surgeon education, and advocacy for patient access and reimbursement policies.
Mynosys Cellular Devices
Series B in 2016
Mynosys Cellular Devices is a global ophthalmic technology company dedicated to providing surgeons with innovative solutions that enable procedural excellence
